UBS AM’s Contineum Therapeutics CTNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.69K Buy
+275
New +$4.1K ﹤0.01% 3966

Other funds holding CTNM

UBS AM's CTNM Position: Q3 2026 in Review

UBS AM opened a new position in Contineum Therapeutics (CTNM) in Q3 2026: 275 shares worth $3.69K. The stake represents ﹤0.01% of the portfolio and ranks #3966 among its holdings.

86 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • UBS AM held 275 shares of Contineum Therapeutics worth $3.69K as of Q3 2026.
  • Contineum Therapeutics was a new UBS AM position in Q3 2026.
  • Contineum Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #3966 holding.
  • 86 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.